Analysts at Societe Generale downgraded Apple Inc. (AAPL) from ‘Buy‘ to ‘Hold‘ in a research report issued to clients on Wednesday.
On valuation measures, Apple Inc. stock it’s trading at a forward P/E multiple of 13.45x, and at a multiple of 17.03x this year’s estimated earnings. The t-12-month revenue at Apple is $199.80 billion. AAPL ‘s ROE for the same period is 35.15%.
Shares of the $732.66 billion market cap company are up 69% year-over-year and 14.61% year-to-date.
Apple Inc., currently with a median Wall Street price target of $145.00 and a high target of $180.00, dropped $0.23 to $125.78 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
Yingli Green Energy Holding Co. Ltd. (YGE) was downgraded from ‘Neutral‘ to ‘Underperform‘ at BofA/Merrill (BAC).
Shares have traded today between $1.86 and $1.93 with the price of the stock fluctuating between $1.75 to $4.65 over the last 52 weeks.
Yingli Green Energy Holding shares have a t-12 price/sales ratio of 0.16. EPS for the same period registers at ($1.21).
Shares of YGE have gained $0.02 to $1.93 in mid-day trading on Wednesday, giving it a market cap of roughly $350 million. The stock traded as high as $4.65 in April 23, 2014.
Bank of America (BAC) reported on Wednesday that they have lowered their rating for Trina Solar Limited (TSL). The firm has downgraded TSL from ‘Buy‘ to ‘Neutral‘.
Trina Solar Ltd. ADS recently traded at $11.99, a loss of $0.10 over Tuesday’s closing price. The name has a current market capitalization of $1.01 billion.
Momenta Pharmaceuticals Inc. (MNTA) had its rating lowered to ‘Neutral’ from ‘Buy’ by analysts at UBS on Wednesday. Currently there are 5 analysts that rate MNTA a ‘Buy’, 1 analyst rates it a ‘Sell’, and 2 rate it a ‘Hold’.
MNTA was up $0.30 at $16.24 in mid-day trade, moving within a 52-week range of $9.38 to $16.35. The name, valued at $865.85 million, opened at $16.00.
On valuation measures, Momenta Pharmaceuticals Inc. shares have a t-12 price/sales ratio of 16.26. EPS for the same period registers at ($1.91).
Teva Pharmaceutical Industries Limited (TEVA) was downgraded by Standpoint Research from a ‘Buy‘ rating to a ‘Hold‘ rating in a research report issued to clients on Wednesday.
TEVA closed at $64.25 on Tuesday and is currently trading up $2.05.
In the past 52 weeks, shares of the company have traded between a low of $47.36 and a high of $67.32 and are now trading at $66.30. Shares are up 24.32% year-over-year and 12.38% year-to-date.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!